Microcrystalline Cellulose (MCC) Market Size, Share, and Growth Forecast for 2025 - 2032

The global microcrystalline cellulose market size is likely to increase from US$1,556.9 Mn in 2025 to US$2,504.6 Mn by 2032, growing at a CAGR of 7.0% during the forecast period 2025 - 2032, driven by rising demand from the pharmaceutical, food & beverage, and personal care industries. In pharmaceuticals, its role as a binder and stabilizer in tablet formulations is expanding as drug production scales up globally.

Key Industry Highlights:

• Leading Region: Europe leads with 30.8% share in 2025, supported by premium food product use, strict pharmaceutical quality compliance, advanced healthcare systems, and rising clean-label and plant-based trends driving MCC adoption in functional foods and dairy alternatives.
• Fastest-Growing Region: Asia Pacific is the fastest-growing region, driven by China, Japan, and India’s pharmaceutical and food processing industries, abundant cotton linter availability, and expansions by producers like Sigachi Industries and Asahi Kasei securing high-performance MCC grades.
• Dominant Raw Material: Refined wood pulp holds 84.5% share in 2025 due to abundant supply, cost-effectiveness, and high purity, ensuring scalable, regulatory-compliant MCC production for pharmaceuticals, nutraceuticals, and functional foods.
• Leading End-use: Pharmaceuticals and nutraceuticals account for 57.6% of the market, driven by global tablet and capsule demand, rising generics, lifestyle disease prevalence, and increasing nutraceutical consumption.
• Key Developments: In May 2025, Roquette acquired IFF Pharma Solutions to expand its MCC portfolio, and in February 2024, Asahi Kasei advanced Ceolus™ grades with low nitrite levels.

Growth Driver: Standardization of Pharmaceutical Excipients and Advanced Formulation Trends Drive Microcrystalline Cellulose Demand

The rising demand for microcrystalline cellulose is driven by the pharmaceutical industry’s growing focus on excipient standardization, regulatory compliance, and the development of advanced drug formulations. MCC provides superior compressibility, flowability, and chemical stability, making it essential in tablets and capsules to ensure dose uniformity, controlled release, and high-performance oral solid dosage forms.

Global healthcare spending trends further support this growth, as Europe’s pharmaceutical production reached US$ 425 billion in 2023 with approximately US$ 50 billion invested in research and development. While U.S. National Healthcare Expenditure is projected to reach US$ 6.19 trillion by 2028. MCC plays a multifunctional role in modern drug delivery systems, enabling high-speed production, direct compression, and patient-centric formulations.

The emphasis on consistent, traceable, and plant-derived excipients strengthens its adoption. As personalized medicine and complex oral solid dosage forms continue to expand, MCC aligns with industry goals of therapeutic efficacy, operational efficiency, and global market access, establishing itself as a critical enabler for next-generation pharmaceuticals.

Restraint: Competitive Pressure from Alternative Cellulose Derivatives

The global microcrystalline cellulose market faces challenges from cellulose alternatives such as carboxymethyl cellulose (CMC) and hydroxypropyl methylcellulose (HPMC), which offer similar binding, thickening, and stabilizing functions at lower cost. These substitutes dominate cost-sensitive sectors, including paints, coatings, and basic adhesives, where MCC’s superior compressibility and stability may not justify its premium pricing.

Although MCC offers a renewable origin and high-performance advantages, pricing and substitution risk limit adoption in non-core industrial applications. Producers are mitigating this through innovative high-performance MCC grades like Sigachi Industries’ co-processed HiCel series and Asahi Kasei’s Ceolus™ UF, which improve compactibility, flow, and formulation efficiency.

Without scaling production or enhancing cost competitiveness, MCC may continue to face barriers in price-driven markets. Differentiation through functional superiority and specialty grades remains critical to maintaining MCC’s relevance across pharmaceutical and industrial segments.

Opportunity: Paints and Coatings Industry Adopting MCC as a Texture and Viscosity Improving Agent

Microcrystalline cellulose is increasingly adopted in the paints and coatings industry for its rheological and texture-modifying properties, stabilizing formulations, preventing pigment settling, and maintaining uniform viscosity. MCC enhances film stability, opacity, and surface coverage while replacing synthetic additives, supporting eco-friendly, low-VOC, and water-based coatings aligned with global environmental regulations.

Leading producers, including Asahi Kasei, Nordic Bioproducts, and Sigachi Industries, are expanding high-purity MCC grades with controlled particle size and co-processed variants to optimize flowability and dispersion for premium architectural and industrial coatings. The natural origin, biodegradability, and sustainability of MCC strengthen its appeal amid growing green building and low-emission mandates.

By integrating cellulose-based excipients, manufacturers achieve superior texture, application performance, and circular economy compliance, presenting a strategic growth opportunity for MCC beyond pharmaceuticals and nutraceuticals in industrial innovation and sustainable formulation development.

Raw Material Insights

Refined wood pulp dominates the global microcrystalline cellulose market, contributing a significant 84.5% share of the total revenue in 2025. The dominance of refined wood pulp is attributed to its abundant availability, cost-effectiveness, and high compatibility in producing pharmaceutical-grade MCC.

Its superior purity levels make it the preferred choice for applications in excipients, stabilizers, and food formulations. The segment benefits from increasing demand in pharmaceutical manufacturing, where stringent regulatory compliance and consistent quality are critical.

Moreover, the growing focus on sustainable and renewable sources for industrial production further reinforces the reliance on refined wood pulp. With industries such as pharmaceuticals, food and beverages, and cosmetics increasingly prioritizing functional, natural ingredients, refined wood pulp-based MCC continues to lead market growth. Its established supply chain and scalable production capacity ensure it retains a dominant position against cotton linters and other alternatives.

End-use Insights

The pharmaceutical and nutraceutical sector is the leading end-use segment for microcrystalline cellulose, commanding 57.6% of the global market share in 2025. MCC plays a crucial role as a binder, filler, and disintegrant in tablet and capsule formulations, ensuring consistent dosage and improved drug stability.

The sector’s dominance is driven by rising global pharmaceutical production, increasing generic drug consumption, and the growing prevalence of lifestyle-related diseases, fueling medicine demand. Nutraceuticals are also gaining momentum as consumers increasingly adopt preventive healthcare solutions.

The adoption of MCC in advanced drug delivery systems enhances patient compliance and product effectiveness, further solidifying its leadership. With regulatory agencies endorsing MCC as a safe excipient and pharmaceutical companies investing in efficient formulations, demand continues to rise. This segment’s sustained growth is also supported by expanding healthcare access in emerging economies, making it the strongest driver of MCC consumption globally.

North America Microcrystalline Cellulose Market Trends

North America accounts for 25.3% of the global microcrystalline cellulose market, driven by its advanced pharmaceutical manufacturing base, high nutraceutical consumption, and strong regulatory frameworks. MCC demand is rising in generic drug formulations, where it functions as a crucial excipient ensuring tablet stability, compressibility, and uniformity.

Technological advancements in MCC grades, such as DFE Pharma’s Pharmacel® sMCC 90, enhance powder flow and compressibility, enabling manufacturers to develop complex formulations efficiently. Strategic expansions by global players, including Sigachi Industries’ advanced MCC grades and Roquette’s acquisition of IFF Pharma Solutions, strengthen supply chains while introducing high-purity and co-processed MCC options.

High-productivity grades like Asahi Kasei’s Ceolus™ UF meet growing demand for robust formulation solutions. With North America’s focus on affordable healthcare and generic drug adoption, MCC’s superior performance in high-speed tablet production and innovative dosage forms reinforces its pivotal role in the pharmaceutical sector.

Europe Microcrystalline Cellulose Market Trends

Europe represents 30.8% of the global MCC market, led by widespread use in premium food products, strict pharmaceutical quality compliance, and a mature healthcare sector. Rising clean-label and plant-based trends have accelerated MCC adoption, particularly in functional foods, low-fat formulations, and dairy alternatives, where it serves as a stabilizer, fat replacer, and texturizer without adding calories.

High-purity MCC grades, produced using technologies like Nordic Bioproducts’ AaltoCell™, ensure regulatory compliance and sustainability, supporting EU green initiatives. MCC is increasingly used in bakery, dairy, and plant-based segments to enhance mouthfeel and texture, meeting growing health-conscious consumer demand.

Large-scale expansions, including EXCiPACT-certified facilities and investments in high-performance MCC grades by Asahi Kasei, secure a reliable supply for food and pharmaceutical manufacturers. These trends position MCC as an essential cellulose-based additive in Europe, catering to premium, health-focused, and sustainable product portfolios.

Asia Pacific Microcrystalline Cellulose Market Trends

Asia-Pacific dominates global MCC production, led by China, Japan, and India, driven by established pharmaceutical and food processing industries, abundant cotton linter raw material, and strong health and wellness demand. In Japan, Asahi Kasei’s JP¥ 13 billion Ceolus™ plant expansion secures capacity for high-performance, nitrosamine-free MCC grades critical for high-speed tablet production.

China provides cost-efficient MCC manufacturing and a robust consumption base across pharmaceuticals, food, and cosmetics. India is emerging as a key hub, with producers like Sigachi Industries expanding advanced MCC grades and integrated API facilities, reporting 25.42% revenue growth and 46.21% EBITDA growth in FY25, serving over 65 countries.

Co-processed MCC grades and strategic acquisitions, such as Oji Holdings’ Chemfield Cellulose takeover, strengthen sustainable supply chains. International certifications like EXCiPACT and ISO 14001 ensure quality and regulatory compliance. Asia-Pacific’s cost-effective production, raw material advantage, and technological innovations consolidate its position as the preferred MCC sourcing region for global pharmaceutical, food, and industrial applications.

The global microcrystalline cellulose market is dominated by a few key players who collectively hold about 60% share.

Companies such as IFF Pharma Solutions, Mingtai Chemical, Sigachi Industries, and Asahi Kasei Corporation lead the industry with significant production capacities and high utilization rates. These top players benefit from strong manufacturing capabilities and extensive distribution networks, enabling them to effectively serve a wide range of end-use industries, including pharmaceuticals, food, and cosmetics.

The remaining 40% of the market is made up of numerous smaller companies that operate regionally or focus on niche segments. These players, while smaller in scale, contribute to the overall market by catering to specialized demands and specific geographic areas.

Given this distribution, the MCC market can be described as oligopolistic in nature, where a handful of dominant firms control the majority of production and sales, while several smaller participants maintain a competitive presence in targeted segments.

Latest Industry Developments

• In February, 2024, Asahi Kasei announced a technological advancement in its Ceolus™ microcrystalline cellulose product line by successfully reducing nitrite concentration levels to 0.1 ppm or less across various grades. The development reinforces Asahi Kasei’s commitment to product safety and positions Ceolus™ as a preferred pharmaceutical excipient for manufacturers seeking low-impurity, high-performance MCC solutions.
• In May, 2025, Roquette has completed the acquisition of IFF Pharma Solutions to expand its pharmaceutical excipient portfolio, including microcrystalline cellulose portfolio. This acquisition strengthens Roquette’s position in the global pharmaceutical market by integrating IFF’s expertise and innovative solutions.